

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO SUBSCRIPTION OF
NEW SHARES UNDER GENERAL MANDATE**

Reference is made to the announcement of Meilleure Health International Industry Group Limited (the “Company”) dated 10 June 2016 in relation to the subscription of 375,300,000 new Shares under General Mandate (the “Announcement”) and the annual report of the Company for the year ended 31 December 2016 (the “Annual Report”). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless otherwise stated.

INTENDED USE OF THE PROCEED FROM THE SUBSCRIPTION OF NEW SHARES

As disclosed in the Announcement, the net proceeds from the subscription of 375,300,000 new Shares would be approximately HK\$106,365,200, which would be used to enlarge its capital base and prepare for any business development opportunities as and when they arise.

ACTUAL USE OF THE PROCEEDS FROM THE SUBSCRIPTION OF NEW SHARES

As disclosed at page 5 of the Annual Report, the subscription was completed on 4 July 2016. As at the date of this announcement, the net proceeds from the subscription of new Shares were fully utilised as follows: (i) approximately HK\$57.60 million has been used as cash consideration in respect of the acquisition of 100% equity interest in Golden Image Investment Limited; and (ii) approximately HK\$48.77 million has been utilised as general working capital of the Group.

By Order of the Board

Meilleure Health International Industry Group Limited

Zhou Wen Chuan

Chief Executive Officer

Hong Kong, 15 August 2017

As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Mr. Liu Lailin and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zhenhua as non-executive Director and Mr. Gao Guanjiang, Professor Chau Chi Wai, Wilton and Ms. Jing Zhang Brogle as independent non-executive Directors.